Baudouin (Bo) Standaert studied medicine (MD) and Tropical Medicine by 1973.
He started his career with mixed work assignments in academia, abroad, and in the public sector (Provincial Institute of Hygiene in Antwerp).
In 1995 Bo joined AMGEN to start with Health Economics (HE) in Europe. In 2005, Bo moved to GSK Vaccines, Wavre, Belgium.
He worked on the many new vaccines that came on the market including Rotarix, Cervarix and Synflorix. The HE-team in Wavre has a wide experience in developing different economic assessments from back-of-the-envelope models to dynamic and macro-economic models.
The team explores new economic value evidence (Quality of Care, absenteeism, herd effect) and, away from cost-effectiveness analysis, optimisation modelling, return on investment, and fiscal modelling.
Bo obtained his PhD on health economics at the Rijksuniversiteit of Groningen, the Netherlands, in 2015. He was the industrial representative at the WHO-IVIR-working group from 2009 to 2017.
He co-chaired the taskforce on economic evaluation of vaccines for ISPOR (2016-2018) and was recently appointed industrial lead for the European IMI-Vital (2019-2023) project on vaccination in elderly.